Cargando…
Alterations in erythrocyte membrane transporter expression levels in type 2 diabetic patients
Type 2 diabetes mellitus (T2DM) is one of the most common multifactorial diseases and several membrane transporters are involved in its development, complications and treatment. We have recently developed a flow-cytometry assay panel for the quantitative determination of red cell membrane protein le...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7854743/ https://www.ncbi.nlm.nih.gov/pubmed/33531564 http://dx.doi.org/10.1038/s41598-021-82417-8 |
_version_ | 1783646147571613696 |
---|---|
author | Szabó, Edit Kulin, Anna Korányi, László Literáti-Nagy, Botond Cserepes, Judit Somogyi, Anikó Sarkadi, Balázs Várady, György |
author_facet | Szabó, Edit Kulin, Anna Korányi, László Literáti-Nagy, Botond Cserepes, Judit Somogyi, Anikó Sarkadi, Balázs Várady, György |
author_sort | Szabó, Edit |
collection | PubMed |
description | Type 2 diabetes mellitus (T2DM) is one of the most common multifactorial diseases and several membrane transporters are involved in its development, complications and treatment. We have recently developed a flow-cytometry assay panel for the quantitative determination of red cell membrane protein levels with potential relevance in diseases. Here we report a detailed phenotypic analysis of a medium scale, clinically based study on the expression of T2DM-related membrane proteins, the GLUT1, GLUT3, MCT1, URAT1, ABCA1, ABCG2 and the PMCA4 transporters in erythrocytes. By comparing age-matched control subjects and three groups of T2DM patients (recently diagnosed, successfully managed, and patients with disease-related complications), we found significant differences in the membrane expression levels of the transporters in these groups. This is a first detailed analysis of T2DM related alterations in erythrocyte membrane transporter protein levels, and the results suggest significant changes in some of the transporter expression levels in various patient groups. By performing a further, more detailed analysis of the clinical and molecular biology parameters, these data may serve as a basis of establishing new, personalized diagnostic markers helping the prevention and treatment of type 2 diabetes. |
format | Online Article Text |
id | pubmed-7854743 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-78547432021-02-04 Alterations in erythrocyte membrane transporter expression levels in type 2 diabetic patients Szabó, Edit Kulin, Anna Korányi, László Literáti-Nagy, Botond Cserepes, Judit Somogyi, Anikó Sarkadi, Balázs Várady, György Sci Rep Article Type 2 diabetes mellitus (T2DM) is one of the most common multifactorial diseases and several membrane transporters are involved in its development, complications and treatment. We have recently developed a flow-cytometry assay panel for the quantitative determination of red cell membrane protein levels with potential relevance in diseases. Here we report a detailed phenotypic analysis of a medium scale, clinically based study on the expression of T2DM-related membrane proteins, the GLUT1, GLUT3, MCT1, URAT1, ABCA1, ABCG2 and the PMCA4 transporters in erythrocytes. By comparing age-matched control subjects and three groups of T2DM patients (recently diagnosed, successfully managed, and patients with disease-related complications), we found significant differences in the membrane expression levels of the transporters in these groups. This is a first detailed analysis of T2DM related alterations in erythrocyte membrane transporter protein levels, and the results suggest significant changes in some of the transporter expression levels in various patient groups. By performing a further, more detailed analysis of the clinical and molecular biology parameters, these data may serve as a basis of establishing new, personalized diagnostic markers helping the prevention and treatment of type 2 diabetes. Nature Publishing Group UK 2021-02-02 /pmc/articles/PMC7854743/ /pubmed/33531564 http://dx.doi.org/10.1038/s41598-021-82417-8 Text en © The Author(s) 2021 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Article Szabó, Edit Kulin, Anna Korányi, László Literáti-Nagy, Botond Cserepes, Judit Somogyi, Anikó Sarkadi, Balázs Várady, György Alterations in erythrocyte membrane transporter expression levels in type 2 diabetic patients |
title | Alterations in erythrocyte membrane transporter expression levels in type 2 diabetic patients |
title_full | Alterations in erythrocyte membrane transporter expression levels in type 2 diabetic patients |
title_fullStr | Alterations in erythrocyte membrane transporter expression levels in type 2 diabetic patients |
title_full_unstemmed | Alterations in erythrocyte membrane transporter expression levels in type 2 diabetic patients |
title_short | Alterations in erythrocyte membrane transporter expression levels in type 2 diabetic patients |
title_sort | alterations in erythrocyte membrane transporter expression levels in type 2 diabetic patients |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7854743/ https://www.ncbi.nlm.nih.gov/pubmed/33531564 http://dx.doi.org/10.1038/s41598-021-82417-8 |
work_keys_str_mv | AT szaboedit alterationsinerythrocytemembranetransporterexpressionlevelsintype2diabeticpatients AT kulinanna alterationsinerythrocytemembranetransporterexpressionlevelsintype2diabeticpatients AT koranyilaszlo alterationsinerythrocytemembranetransporterexpressionlevelsintype2diabeticpatients AT literatinagybotond alterationsinerythrocytemembranetransporterexpressionlevelsintype2diabeticpatients AT cserepesjudit alterationsinerythrocytemembranetransporterexpressionlevelsintype2diabeticpatients AT somogyianiko alterationsinerythrocytemembranetransporterexpressionlevelsintype2diabeticpatients AT sarkadibalazs alterationsinerythrocytemembranetransporterexpressionlevelsintype2diabeticpatients AT varadygyorgy alterationsinerythrocytemembranetransporterexpressionlevelsintype2diabeticpatients |